Ann: Notice of Annual General Meeting/Proxy Form, page-21

Thank you for your post Promojoe!

I indeed do not have an eight ball to predict anything with certainty, but I have actively invested and worked in biotech for 30 plus years now.

My investment interest in Australia is usually restricted to a few companies I find at the verge of breakthrough from research to commercial partnerships.
ADO, in that respect, is overdue to deliver.

The technology has peaked my interest some years back and since then I have actively traded the stock, currently extended my holding far beyond my original target, simply due to the fact that the stock was driven to incredible low prices, not reflecting positive milestone developments with many partners.


The industry Anteo is involved in is extremely slow moving and many globals we dealt with preferred inferior tests and applications to change.
That is the nature of this industry.
It only takes one though to chose innovation and off we go.
Additionally, new leadership might be prepared to offer exclusivity, a hurdle which caused several past partnerships to fail as it was not offered.

Alternatively, several domestic partnerships paving the way to organic growth models, preparing a larger breakthrough from a base of strength.
That is exactly where BOD went wrong in the past 2 years, it attempted to jump several hurdles at once and failed.

This does not though reflect, in my opinion, on the technology, but on naive trading and loan arrangements.


I stay committed to this company and will see my investment through.
Of course, I can not predict the outcome, but experience lets one anticipate market movements due to emotionally charged and bias market forces.
The current buying and volume seem to indicate to me that a swap and churn is currently unfolding for ADO which usually should not take longer than 2 weeks.
AGMs are usually events for a company which can create directional change and leadership impetus.
I expect these developments for the upcoming AGM.

cheers
Surges